首页> 外文期刊>Southern Medical Journal >Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration.
【24h】

Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration.

机译:内镜逆行胰胆管造影术对梗阻性黄疸患者使用厄他培南的预防:安全性,有效性和胆汁渗透性。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Cholangitis and biliary sepsis are rare but serious complications of endoscopic retrograde cholangiopancreatography (ERCP). The aim of this study is to investigate the safety, efficacy, and biliary penetration of ertapenem, a newer carbapenem with a long half-life and broad-spectrum antimicrobial activity, for ERCP prophylaxis. METHODS: Patients with obstructive jaundice without cholangitis received a single dose of ertapenem equal to 1 gram intravenously prior to ERCP. A 2-3 mL bile sample was collected after cannulation and prior to contrast injection. Patients were observed for 72 hours for cholangitis or drug-related adverse events. Biliary ertapenem levels were measured using high-performance liquid chromatography (HPLC). RESULTS: Twenty-eight patients (ages 18-87 years, M/F ratio 1:1) were enrolled. Seven had no cholestasis and were included to study ertapenem penetration in unobstructed biliary trees. Cannulation was achieved in all patients. One patient (3.6%) with persistent intrahepatic stones developed cholangitis. No drug-related adverse events were noted. The mean time from ertapenem administration to bile collection was 60 +/- 24 minutes. There was a significant negative correlation between serum bilirubin and biliary ertapenem levels (r = -0.542, P = 0.003) with the highest level (6.25 mug/mL) noted in unobstructed biliary systems. CONCLUSION: Ertapenem appears to be a safe and effective prophylaxis in patients with obstructive jaundice undergoing ERCP despite a limited biliary penetration in patients with high-grade obstruction.
机译:背景:胆管炎和胆道败血症很少见,但内镜逆行胰胆管造影(ERCP)的严重并发症。这项研究的目的是研究ertapenem(一种具有较长半衰期和广谱抗菌活性的新型碳青霉烯)的安全性,疗效和胆汁渗透性,以预防ERCP。方法:ERCP之前,静脉无阻塞性黄疸的患者接受单剂量的厄他培南,相当于1克静脉注射。在插管后和造影剂注射之前收集2-3 mL胆汁样品。观察患者72小时的胆管炎或药物相关不良事件。使用高效液相色谱法(HPLC)测量胆碱酯酶水平。结果:28例患者(年龄18-87岁,男女比例为1:1)。七个没有胆汁淤积,被纳入研究厄他培南在通畅的胆道树中的渗透。所有患者均完成插管。一名患有持续性肝内结石的患者(3.6%)发展为胆管炎。没有发现与药物相关的不良事件。从服用厄他培南到收集胆汁的平均时间为60 +/- 24分钟。在通畅的胆道系统中,血清胆红素和胆碱酯酶水平之间存在显着的负相关(r = -0.542,P = 0.003),最高水平为(6.25ug / mL)。结论:厄他培南对患有ERCP的梗阻性黄疸患者似乎是一种安全有效的预防措施,尽管严重梗阻患者的胆汁渗透率有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号